1. Wong, S. & Witte, O. N. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22, 247–306. https://doi.org/10. 1146/annurev.immunol.22.012703.104753 (2004).
2. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330–1340. https://doi.org/10.1056/nejm199904293401706 (1999).
3. Braun, T. P., Eide, C. A. & Druker, B. J. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37, 530–542. https:// doi.org/10.1016/j.ccell.2020.03.006 (2020).
4. Ross, D. M. & Hughes, T. P. Treatment-free remission in patients with chronic myeloid leukaemia. Nat. Rev. Clin. Oncol. 17, 493–503. https://doi.org/10.1038/s41571-020-0367-1 (2020).
5. Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1–10. https://doi.org/10.1016/j. immuni.2013.07.012 (2013).
6. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355. https://doi.org/10.1126/ science.aar4060 (2018).
7. Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434–452. https://doi. org/10.1016/j.immuni.2018.03.014 (2018).
8. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469. https://doi.org/10.1126/science.aaf1490 (2016).
9. Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462–2465 (1990).
10. Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041–2050 (1995).
11. Biernacki, M. A. et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 70, 906–915. https://doi.org/10.1158/0008-5472.CAN-09-2303 (2010).
12. Talpaz, M., Hehlmann, R., Quintas-Cardama, A., Mercer, J. & Cortes, J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 27, 803–812. https://doi.org/10.1038/leu.2012.313 (2013).
13. Hughes, A. & Yong, A. S. M. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front. Immunol. 8, 469. https://doi.org/10.3389/fimmu.2017.00469 (2017).
14. Rea, D. et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study. Haematologica 102, 1368–1377. https://doi.org/10.3324/haematol.2017.165001 (2017).
15. Bruck, O. et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32, 1643–1656. https://doi.org/10.1038/s41375-018-0175-0 (2018).
16. Tarafdar, A. & Hopcroft, L. E. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood 129, 199–208. https://doi.org/10.1182/blood-2016-09-742049 (2017).
17. Paquette, R. L. et al. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 16, 1484–1489. https://doi.org/10.1038/sj.leu.2402602 (2002).
18. Boissel, N. et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18, 1656–1661. https://doi.org/10.1038/sj.leu.2403474 (2004).
19. Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535–584. https://doi.org/10.1146/annurev.immunol.26.021607.090400 (2008).
20. Murphy, T. L. et al. Transcriptional control of dendritic cell development. Annu. Rev. Immunol. 34, 93–119. https://doi.org/10. 1146/annurev-immunol-032713-120204 (2016).
21. Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250. https://doi.org/10.1038/s41467-018-03600-6 (2018).
22. Watanabe, T. et al. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelog- enous leukemia. Cancer Res. 73, 6642–6653. https://doi.org/10.1158/0008-5472.CAN-13-0802 (2013).
23. Kurotaki, D. et al. Transcription factor IRF8 governs enhancer landscape dynamics in mononuclear phagocyte progenitors. Cell Rep. 22, 2628–2641. https://doi.org/10.1016/j.celrep.2018.02.048 (2018).
24. Iwasaki, H. & Akashi, K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 26, 726–740. https://doi.org/ 10.1016/j.immuni.2007.06.004 (2007).
25. Sumide, K. et al. A revised road map for the commitment of human cord blood CD34-negative hematopoietic stem cells. Nat. Commun. 9, 2202. https://doi.org/10.1038/s41467-018-04441-z (2018).
26. Breton, G., Lee, J., Liu, K. & Nussenzweig, M. C. Defining human dendritic cell progenitors by multiparametric flow cytometry. Nat. Protoc. 10, 1407–1422. https://doi.org/10.1038/nprot.2015.092 (2015).
27. Cytlak, U. et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. Immunity https://doi.org/10.1016/j.immuni.2020.07.003 (2020).
28. Diaz-Blanco, E. et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21, 494–504. https://doi.org/10.1038/sj.leu.2404549 (2007).
29. Durai, V. et al. Altered compensatory cytokine signaling underlies the discrepancy between Flt3(-/-) and Flt3l(-/-) mice. J. Exp. Med. 215, 1417–1435. https://doi.org/10.1084/jem.20171784 (2018).
30. Onai, N. et al. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat. Immunol. 8, 1207–1216. https://doi.org/10.1038/ni1518 (2007).
31. Kurotaki, D. et al. IRF8 inhibits C/EBPalpha activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat. Commun. 5, 4978. https://doi.org/10.1038/ncomms5978 (2014).
32. Tamura, T., Nagamura-Inoue, T., Shmeltzer, Z., Kuwata, T. & Ozato, K. ICSBP directs bipotential myeloid progenitor cells to dif- ferentiate into mature macrophages. Immunity 13, 155–165. https://doi.org/10.1016/s1074-7613(00)00016-9 (2000).
33. Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317. https://doi.org/10.1016/s0092-8674(00)81348-3 (1996).
34. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268. https://doi.org/10.1038/nri3175 (2012).
35. Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108–119. https://doi. org/10.1038/s41590-017-0022-x (2018).
36. Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462. https://doi. org/10.1038/nrc.2016.54 (2016).
37. Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24. https://doi.org/10. 1038/s41577-019-0210-z (2020).
38. Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer https://doi.org/10.1038/ s41568-020-0281-y (2020).
39. Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: Neutral no more. Nat. Rev. Cancer 16, 431–446. https:// doi.org/10.1038/nrc.2016.52 (2016).
40. Condamine, T. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1, 8943. https://doi.org/10.1126/sciimmunol.aaf8943 (2016).
41. Rice, C. M. et al. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat. Commun. 9, 5099. https://doi.org/10.1038/s41467-018-07505-2 (2018).
42. Christiansson, L. et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE 8, e55818. https://doi.org/10.1371/ journal.pone.0055818 (2013).
43. Mumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M. & Ochsenbein, A. F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114, 1528–1536. https://doi.org/10.1182/blood advances.201600081010.1182/blood-2008-09-179697 (2009).
44. Kantarjian, H. M. et al. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66, 1326–1335 (1985).
45. Kok, C. H. & Yeung, D. T. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 3, 1610–1621. https://doi.org/10.1182/bloodadvances.2019000195 (2019).
46. Radich, J. P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 103, 2794–2799. https://doi.org/10.1073/pnas.0510423103 (2006).
47. Chauvistré, H. et al. Dendritic cell development requires histone deacetylase activity. Eur. J. Immunol. 44, 2478–2488. https://doi. org/10.1002/eji.201344150 (2014).
48. Lee, J. et al. Lineage specification of human dendritic cells is marked by IRF8 expression in hematopoietic stem cells and multipotent progenitors. Nat. Immunol. 18, 877–888. https://doi.org/10.1038/ni.3789 (2017).
49. Kurotaki, D. et al. Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice. Blood 133, 1803–1813. https://doi.org/10.1182/blood-2018-06-857789 (2019).
50. Welner, R. S. et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and pro- genitor cells. Cancer Cell 27, 671–681. https://doi.org/10.1016/j.ccell.2015.04.004 (2015).
51. Prestipino, A. & Emhardt, A. J. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaam7229. https://doi.org/10.1126/scitranslmed.aam7729 (2018).
52. Sasaki, H. et al. Transcription factor IRF8 plays a critical role in the development of murine basophils and mast cells. Blood 125, 358–369. https://doi.org/10.1182/blood-2014-02-557983 (2015).
53. Hjort, E. E., Huang, W., Hu, L. & Eklund, E. A. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. Oncotarget 7, 77635–77650. https://doi.org/10.18632/oncotarget. 12749 (2016).
54. Waight, J. D., Banik, D., Griffiths, E. A., Nemeth, M. J. & Abrams, S. I. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J. Biol. Chem. 289, 15642–15652. https://doi.org/10.1074/jbc.M113.544320 (2014).
55. Qi, X. et al. Antagonistic regulation by the transcription factors C/EBPα and MITF specifies basophil and mast cell fates. Immunity 39, 97–110. https://doi.org/10.1016/j.immuni.2013.06.012 (2013).
56. Esashi, E. et al. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28, 509–520. https://doi.org/10.1016/j.immuni.2008.02.013 (2008).
57. Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M. & Kroemer, G. Immunological off-target effects of imatinib. Nat. Rev. Clin. Oncol. 13, 431–446. https://doi.org/10.1038/nrclinonc.2016.41 (2016).
58. Molldrem, J. J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Investig. 111, 639–647. https://doi.org/10.1172/JCI16398 (2003).
59. Ichihara, K. et al. Collaborative derivation of reference intervals for major clinical laboratory tests in Japan. Ann. Clin. Biochem. 53, 347–356. https://doi.org/10.1177/0004563215608875 (2016).
60. Lundberg, K. et al. Allergen-specific immunotherapy alters the frequency, as well as the FcR and CLR expression profiles of human dendritic cell subsets. PLoS ONE 11, e0148838. https://doi.org/10.1371/journal.pone.0148838 (2015).